Agomelatine |
Formulary
|
Tablets 25mg Major Depressive Episodes. with prior approval. LSCFT to approve all applications to use - patients currently on treatment can continue. |
LSCFT - Agomelatine medicine request form MHRA: Agomelatine (Valdoxan): risk of liver toxicity |
|
Duloxetine Cymbalta® |
Formulary
|
Capsules (Cymbalta®) 30mg, 60mg Third line use within LSCFT. CAUTION: available as another brand Yentreve for stress urinary incontinence. Recommended that prescriptions state the brand name Cymbalta. |
MHRA: Duloxetine: marketed as Cymbalta▼ and Yentreve▼ for different disorders MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|
Venlafaxine |
Formulary
|
Tablets 37.5mg, 75mg M/R capsules 225mg - to be prescribed as Vencarm XL in primary care Third line use only. Consider cardiovascular history e.g. uncontrolled hypertension, and risk of overdose. Higher propensity for discontinuation. |
MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery |
|